10/4/2022  5:36:24 PM Chg. +0.300 Volume Bid10/4/2022 Ask10/4/2022 Market Capitalization Dividend Y. P/E Ratio
34.700EUR +0.87% 30
Turnover: 1,044
-Bid Size: - -Ask Size: - 1.65 bill.EUR 0.10% -

Business description

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies.
 

Management board & Supervisory board

CEO
-
Management board
Dr. Jörg Schüttrumpf (ab 1.01.2022), Dr. Georg Floß, Dr. Michael Ramroth
Supervisory board
Dr. Bernhard Ehmer, David Bell, Tomás Dagá Gelabert, Uta Kemmerich-Keil
 

Company data

Name: Biotest AG
Address: Landsteinerstraße 5,D-63303 Dreieich
Phone: +49-6103-801-0
Fax: +49-6103-801-150
E-mail: mail@biotest.de
Internet: www.biotest.de
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 100.00%
IPO date: 10/14/1987

Investor relations

Name: Dr. Monika Buttkereit
IR phone: +49-6103-801-4406
IR Fax: +49-6103-801-347
IR e-mail: investor_relations@biotest.de

Company calendar

CW 47 | 11/14/2022 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
100.00%